<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541589</url>
  </required_header>
  <id_info>
    <org_study_id>CCFZ533B2201E1</org_study_id>
    <nct_id>NCT04541589</nct_id>
  </id_info>
  <brief_title>Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome</brief_title>
  <acronym>TWINSS Extn</acronym>
  <official_title>A TWINSS Extension Trial to Evaluate the Safety and Tolerability of CFZ533 (Iscalimab) at Two Dose Levels Administered Subcutaneously in Patients With Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of iscalimab at two dose levels in&#xD;
      patients with Sjögren's Syndrome, who participated in the TWINSS core study,&#xD;
      CCFZ533B2201(NCT03905525). Additionally, this Extension study will further explore the&#xD;
      pharmacokinetics (PK) and efficacy of iscalimab at two dose level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Extension study is a 48-week treatment study, with a safety follow-up period of 12&#xD;
      weeks. This study will evaluate the safety and tolerability of iscalimab at two dose levels&#xD;
      in patients with Sjögren's Syndrome, who must have participated in the TWINSS core study,&#xD;
      CCFZ533B2201 (NCT03905525) and must have completed the entire treatment period up to Week 48&#xD;
      and the follow-up period up to Week 60.&#xD;
&#xD;
      Study treatment will be administered as bi-weekly subcutaneous injections (Q2W s.c.) via&#xD;
      prefilled syringes (PFS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Upon completion of the core study (NCT03905525), Investigators will use their clinical judgment including responder definitions to decide if it is beneficial for participants to continue with the Extension study based upon response to therapy at the end of the treatment period of the core study.&#xD;
Participants will be re-assigned to one of the following two treatment arms:&#xD;
Arm 1 - Iscalimab Dose 1 s.c. Q2W&#xD;
Arm 2 - Iscalimab Dose 2 s.c. Q2W and Placebo&#xD;
At Week 60 of the TWINSS core study (NCT03905525), all eligible participants from the core study can opt to be enrolled in the extension study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This will be a double-blind treatment until the final database lock of Core study (NCT03905525).&#xD;
Participants, Investigator, site staff, and persons performing the assessments will remain blinded to the identity of the treatment until the final database lock of Core study (NCT03905525)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent AEs (TEAEs)</measure>
    <time_frame>60 weeks</time_frame>
    <description>Number and percentage of participants having any AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in laboratory evaluations for hematology from baseline to each study visit</measure>
    <time_frame>60 weeks</time_frame>
    <description>Number and percentage of participants with notable abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in laboratory evaluations for serum chemistry from baseline to each study visit</measure>
    <time_frame>60 weeks</time_frame>
    <description>Number and percentage of participants with notable abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital sign measurements from baseline for each post-baseline visit</measure>
    <time_frame>60 weeks</time_frame>
    <description>Number and percentage of participants with notable abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free iscalimab concentration in plasma during the treatment (Ctrough) and follow-up (up to end of study) periods</measure>
    <time_frame>60 weeks</time_frame>
    <description>To assess the pharmacokinetics (PK trough levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-iscalimab antibodies in plasma at analysis visits up to end of study</measure>
    <time_frame>60 weeks</time_frame>
    <description>To assess immunogenicity of iscalimab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 - Iscalimab Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - Iscalimab Dose 2 and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533 (iscalimab)</intervention_name>
    <description>Biological</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>iscalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CFZ533 Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants eligible for inclusion in this study must meet all of the following criteria:&#xD;
&#xD;
          1. Participants must have participated in the TWINSS core study, CCFZ533B2201&#xD;
             (NCT03905525), and must have completed the entire treatment period up to Week 48 and&#xD;
             the follow-up period up to Week 60&#xD;
&#xD;
          2. Signed informed consent must be obtained prior to participation in the Extension study&#xD;
             (i.e. before commencement of the Week 60 assessments of the core study)&#xD;
&#xD;
          3. In the judgement of the Investigator, participants must be expected to clinically&#xD;
             benefit from continued iscalimab therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting any of the following criteria are not eligible for inclusion in this&#xD;
        study.&#xD;
&#xD;
          1. Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic disease&#xD;
             constitutes the principle illness, specifically:&#xD;
&#xD;
               -  Moderate-to-severe active systemic lupus erythematosus (SLE) with anti-dsDNA&#xD;
                  positivity and renal involvement, or other organ involvement that impedes on&#xD;
                  ability to score ESSDAI domains&#xD;
&#xD;
               -  Active rheumatoid arthritis (RA) that impedes on the ability to score the ESSDAI&#xD;
                  articular domain&#xD;
&#xD;
               -  Systemic sclerosis&#xD;
&#xD;
               -  Any other concurrent connective tissue disease (e.g., lupus nephritis (LN), large&#xD;
                  vessel vasculitis (LVV), Sharp syndrome (mixed connective tissue disease) that is&#xD;
                  active and requires immunosuppressive treatment outside the scope of this trial&#xD;
                  and would impede on Sjögren's Syndrome organ domain assessments&#xD;
&#xD;
          2. Use of other investigational drugs other than iscalimab during the core study&#xD;
&#xD;
          3. Active uncontrolled viral, bacterial or other infections requiring systemic treatment&#xD;
             at the time of enrollment, or history of recurrent clinically significant infection or&#xD;
             of bacterial infections with encapsulated organisms&#xD;
&#xD;
          4. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human Chorionic Gonadotropin (hCG) laboratory test&#xD;
&#xD;
          5. Women of child-bearing potential (WOCBP), defined as all women physiologically capable&#xD;
             of becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             during dosing and for 14 weeks after stopping of investigational drug.&#xD;
&#xD;
          6. Missing ESSDAI (Cohort 1 and Cohort 2) or ESSPRI (Cohort 2) scores in the core study&#xD;
             at Weeks 0 and 4 or Weeks 40 and 48.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <state>Fejer</state>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457 8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sasebo-city</city>
        <state>Nagasaki</state>
        <zip>857-1165</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03905525?term=CCFZ533B2201&amp;draw=2&amp;rank=1</url>
    <description>Core study</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren's Syndrome</keyword>
  <keyword>autoimmune</keyword>
  <keyword>ESSDAI</keyword>
  <keyword>ESSPRI</keyword>
  <keyword>anti-CD40</keyword>
  <keyword>CFZ533</keyword>
  <keyword>iscalimab</keyword>
  <keyword>TWINSS Extension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

